Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
96.94
-0.99 (-1.01%)
At close: Oct 2, 2026, 4:00 PM EDT
96.99
+0.05 (0.05%)
After-hours: Oct 2, 2026, 7:30 PM EDT
Inhibrx Biosciences Employees
As of December 31, 2025, Inhibrx Biosciences had 110 total employees, including 109 full-time and 1 part-time employees. The number of employees decreased by 51 or -31.68% compared to the previous year.
Employees
110
Change (1Y)
-51
Growth (1Y)
-31.68%
Revenue / Employee
n/a
Profits / Employee
-$1,256,191
Market Cap
1.43B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 110 | -51 | -31.68% | 109 | 1 |
| Dec 31, 2024 | 161 | -11 | -6.40% | 156 | 5 |
| Mar 31, 2024 | 176 | - | - | 170 | 6 |
| Dec 31, 2023 | 172 | - | - | 166 | 6 |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Ascentage Pharma Group International | 828 |
| Innoviva | 159 |
| Maze Therapeutics | 141 |
| AnaptysBio | 104 |
| Nanobiotix | 100 |
| Tyra Biosciences | 87 |
| ArriVent BioPharma | 77 |
INBX News
- 11 days ago - Inhibrx director buys $500K in common stock - TheFly
- 26 days ago - Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study - Reuters
- 26 days ago - Inhibrx Biosciences Transcript: Study update - Transcripts
- 26 days ago - Inhibrx Biosciences Press release: Study update - Filings
- 26 days ago - Inhibrx Biosciences Slides: Study update - Filings
- 26 days ago - Inhibrx’s INBRX-106 achieves clinical benefit in Phase 2 HNSCC study - TheFly
- 26 days ago - Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study - PRNewsWire
- 4 weeks ago - Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study - PRNewsWire